Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
P 3 (2)

Trial Status

Active Not Recruiting2
Unknown2
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT03091192Phase 3Active Not Recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT06535568Not ApplicableRecruiting

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

NCT05288166Phase 3Active Not Recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT04340349Early Phase 1Unknown

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals

NCT04556071Phase 2Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Showing all 5 trials

Research Network

Activity Timeline